IFG Advisory LLC Has $531,000 Stock Holdings in GSK plc (NYSE:GSK)

IFG Advisory LLC cut its position in GSK plc (NYSE:GSK) by 15.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 14,335 shares of the pharmaceutical company’s stock after selling 2,637 shares during the period. IFG Advisory LLC’s holdings in GSK were worth $531,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Fairfield Bush & CO. bought a new stake in shares of GSK during the first quarter worth $80,000. JPMorgan Chase & Co. increased its position in shares of GSK by 2.3% during the first quarter. JPMorgan Chase & Co. now owns 241,367 shares of the pharmaceutical company’s stock worth $10,514,000 after acquiring an additional 5,518 shares in the last quarter. Panagora Asset Management Inc. bought a new stake in shares of GSK during the first quarter worth $467,000. Blair William & Co. IL increased its position in shares of GSK by 3.0% during the first quarter. Blair William & Co. IL now owns 37,192 shares of the pharmaceutical company’s stock worth $1,620,000 after acquiring an additional 1,094 shares in the last quarter. Finally, Cetera Investment Advisers increased its position in shares of GSK by 2.4% during the first quarter. Cetera Investment Advisers now owns 62,991 shares of the pharmaceutical company’s stock worth $2,744,000 after acquiring an additional 1,453 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on GSK. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Finally, Morgan Stanley started coverage on shares of GSK in a research report on Tuesday, January 23rd. They issued an “equal weight” rating for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

GSK Stock Down 0.3 %

GSK stock opened at $42.86 on Friday. The company has a market cap of $88.22 billion, a P/E ratio of 14.24, a price-to-earnings-growth ratio of 1.94 and a beta of 0.64. GSK plc has a 1-year low of $33.33 and a 1-year high of $43.84. The company has a fifty day simple moving average of $41.62 and a 200 day simple moving average of $38.35. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 1.19.

GSK (NYSE:GSK) last released its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). The business had revenue of $10 billion during the quarter, compared to the consensus estimate of $9.79 billion. GSK had a net margin of 16.24% and a return on equity of 51.45%. Research analysts anticipate that GSK plc will post 4.07 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd will be paid a $0.3564 dividend. The ex-dividend date is Thursday, February 22nd. This represents a $1.43 dividend on an annualized basis and a yield of 3.33%. This is a boost from GSK’s previous quarterly dividend of $0.34. GSK’s dividend payout ratio (DPR) is currently 52.82%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.